{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T10:20:51Z","timestamp":1783592451832,"version":"3.55.0"},"reference-count":50,"publisher":"Bioscientifica","issue":"6","funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"crossref","award":["RP210143"],"award-info":[{"award-number":["RP210143"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"crossref"}]},{"name":"NCI Cancer Center Support Grant","award":["P30CA125123"],"award-info":[{"award-number":["P30CA125123"]}]},{"name":"NCI Cancer Center Support Grant","award":["P30CA093373"],"award-info":[{"award-number":["P30CA093373"]}]}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Darolutamide is a second-generation androgen receptor (AR) antagonist (2GARA) with established benefit in treating patients with non-metastatic castration-resistant prostate cancer (M0-CRPC) and metastatic castration-sensitive prostate cancer. Its real-world effectiveness in the treatment of patients with metastatic (M1) CRPC, including those who have progressed on CYP17 inhibitors (CYP17Is) or other 2GARAs (enzalutamide\/apalutamide), is not well-described. We assessed the real-world effectiveness of darolutamide in a racially diverse cohort of 44 M1-CRPC and 11 M0-CRPC patients and collected data on baseline and emerging AR mutations in circulating tumor DNA (ctDNA) in these patients. The median progression-free survival (PFS) was 2.15 months for M1-CRPC and 21.16 months for M0-CRPC patients. In the M1-CRPC cohort, the median PFS was longer in those who had only received prior CYP17Is compared to 2GARA-resistant patients (2.43 vs 1.61 months; P = 0.03). Darolutamide suppressed serum PSA levels by &amp;gt;50% in 5\/44 M1-CRPC patients (11.4%), all previously 2GARA-na\u00efve. M1-CRPC patients resistant only to CYP17Is had improved mean best percent PSA changes from baseline compared to 2GARA-resistant patients (4.68 vs 42.34%; P = 0.047). PFS was not significantly different between African-American and non-African-American patients, or between patients with and without AR mutations at baseline. AR mutations emerging or increasing in allele fraction in ctDNA upon darolutamide treatment included H875Y, H100Q, D891H, T878A, L702H, L329W, N767Y and AR copy number gain. In summary, darolutamide may provide some benefit in CYP17I-refractory M1-CRPC patients, even in the presence of AR mutations. Resistance to other 2GARAs may significantly decrease benefit from darolutamide.<\/jats:p>","DOI":"10.1530\/erc-24-0188","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T12:26:25Z","timestamp":1746102385000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":1,"title":["Real-world effectiveness of darolutamide in metastatic castration-resistant prostate cancer"],"prefix":"10.1530","volume":"32","author":[{"given":"Alyssa","family":"Liang","sequence":"first","affiliation":[{"name":"Santa Clara Valley Medical Center 1 , , ,","place":["San Jose, California, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuchi","family":"Gulati","sequence":"additional","affiliation":[{"name":"University of California Davis Comprehensive Cancer Center 2 , , ,","place":["Sacramento, California, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quillan","family":"Huang","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine 3 , , ,","place":["Houston, Texas, USA"]},{"name":"Ben Taub Hospital 4 , , ,","place":["Houston, Texas, USA"]},{"name":"Dan L Duncan Comprehensive Cancer Center 5 , , ,","place":["Houston, Texas, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Dowst","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine 3 , , ,","place":["Houston, Texas, USA"]},{"name":"Dan L Duncan Comprehensive Cancer Center 5 , , ,","place":["Houston, Texas, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aedric","family":"Lim","sequence":"additional","affiliation":[{"name":"University of California Davis Comprehensive Cancer Center 2 , , ,","place":["Sacramento, California, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neda","family":"Zarrin-Khameh","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine 3 , , ,","place":["Houston, Texas, USA"]},{"name":"Ben Taub Hospital 4 , , ,","place":["Houston, Texas, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme","family":"Godoy","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine 3 , , ,","place":["Houston, Texas, USA"]},{"name":"Ben Taub Hospital 4 , , ,","place":["Houston, Texas, USA"]},{"name":"Dan L Duncan Comprehensive Cancer Center 5 , , ,","place":["Houston, Texas, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attiya B","family":"Noor","sequence":"additional","affiliation":[{"name":"Ben Taub Hospital 4 , , ,","place":["Houston, Texas, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Castro","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine 3 , , ,","place":["Houston, Texas, USA"]},{"name":"Dan L Duncan Comprehensive Cancer Center 5 , , ,","place":["Houston, Texas, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E","family":"Scheurer","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine 3 , , ,","place":["Houston, Texas, USA"]},{"name":"Dan L Duncan Comprehensive Cancer Center 5 , , ,","place":["Houston, Texas, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamta","family":"Parikh","sequence":"additional","affiliation":[{"name":"University of California Davis Comprehensive Cancer Center 2 , , ,","place":["Sacramento, California, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Primo N","family":"Lara","sequence":"additional","affiliation":[{"name":"University of California Davis Comprehensive Cancer Center 2 , , ,","place":["Sacramento, California, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Hilsenbeck","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine 3 , , ,","place":["Houston, Texas, USA"]},{"name":"Dan L Duncan Comprehensive Cancer Center 5 , , ,","place":["Houston, Texas, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Mims","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine 3 , , ,","place":["Houston, Texas, USA"]},{"name":"Ben Taub Hospital 4 , , ,","place":["Houston, Texas, USA"]},{"name":"Dan L Duncan Comprehensive Cancer Center 5 , , ,","place":["Houston, Texas, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4659-476X","authenticated-orcid":true,"given":"Nicholas","family":"Mitsiades","sequence":"additional","affiliation":[{"name":"University of California Davis Comprehensive Cancer Center 2 , , ,","place":["Sacramento, California, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,5,1]]},"reference":[{"key":"2026070905480852100_bib1","first-page":"200","article-title":"Imaging and treatment recommendations in patients with castrate-resistant prostate cancer","volume":"19","author":"Albala","year":"2017","journal-title":"Rev Urol"},{"key":"2026070905480852100_bib2","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1158\/2159-8290.CD-17-0937","article-title":"Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer","volume":"8","author":"Annala","year":"2018","journal-title":"Cancer Discov"},{"key":"2026070905480852100_bib3","article-title":"Prevalence and spectrum of AR ligand-binding domain mutations detected in circulating-tumor DNA across disease states in men with metastatic castration-resistant prostate cancer","volume":"8","author":"Antonarakis","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"2026070905480852100_bib4","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026070905480852100_bib5","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.2018.77.9827","article-title":"Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment","volume":"36","author":"Attard","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026070905480852100_bib6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.eururo.2014.06.045","article-title":"Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients","volume":"67","author":"Azad","year":"2015","journal-title":"Eur Urol"},{"key":"2026070905480852100_bib7","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1158\/1078-0432.CCR-14-2666","article-title":"Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer","volume":"21","author":"Azad","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2026070905480852100_bib8","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/pros.24015","article-title":"Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer","volume":"80","author":"Begemann","year":"2020","journal-title":"Prostate"},{"key":"2026070905480852100_bib9","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2013.08.020","article-title":"Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone","volume":"50","author":"Bianchini","year":"2014","journal-title":"Eur J Cancer"},{"key":"2026070905480852100_bib10","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.eururo.2017.08.012","article-title":"Moving towards precision urologic oncology: targeting enzalutamide-resistant prostate cancer and mutated forms of the androgen receptor using the novel inhibitor darolutamide (ODM-201)","volume":"73","author":"Borgmann","year":"2018","journal-title":"Eur Urol"},{"key":"2026070905480852100_bib11","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1158\/1078-0432.CCR-14-1220","article-title":"Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors","volume":"21","author":"Chen","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2026070905480852100_bib12","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"2026070905480852100_bib13","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026070905480852100_bib14","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41391-021-00451-z","article-title":"Racial disparities in prostate cancer among black men: epidemiology and outcomes","volume":"25","author":"Chowdhury-Paulino","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2026070905480852100_bib15","doi-asserted-by":"crossref","first-page":"5667","DOI":"10.2147\/CMAR.S227583","article-title":"Darolutamide: an evidenced-based review of its efficacy and safety in the treatment of prostate cancer","volume":"12","author":"Crawford","year":"2020","journal-title":"Cancer Manag Res"},{"key":"2026070905480852100_bib16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"2026070905480852100_bib17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.eururo.2017.07.035","article-title":"Antitumour activity and safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone acetate plus prednisone for \u226524 weeks in europe","volume":"74","author":"De Bono","year":"2018","journal-title":"Eur Urol"},{"key":"2026070905480852100_bib18","first-page":"211","article-title":"Cancer statistics for African Americans, 2019","volume":"69","author":"Desantis","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"2026070905480852100_bib19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2017.74.2049","article-title":"Racial and ethnic disparities in cancer survival: the contribution of tumor, sociodemographic, institutional, and neighborhood characteristics","volume":"36","author":"Ellis","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026070905480852100_bib20","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(14)70240-2","article-title":"Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial","volume":"15","author":"Fizazi","year":"2014","journal-title":"Lancet Oncol"},{"key":"2026070905480852100_bib21","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"2026070905480852100_bib22","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N Engl J Med"},{"key":"2026070905480852100_bib23","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1002\/cncr.33589","article-title":"A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer","volume":"127","author":"George","year":"2021","journal-title":"Cancer"},{"key":"2026070905480852100_bib24","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41391-021-00463-9","article-title":"Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer","volume":"25","author":"George","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2026070905480852100_bib25","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature11125","article-title":"The mutational landscape of lethal castration-resistant prostate cancer","volume":"487","author":"Grasso","year":"2012","journal-title":"Nature"},{"key":"2026070905480852100_bib26","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"2026070905480852100_bib27","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1016\/S1470-2045(19)30688-6","article-title":"Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial","volume":"20","author":"Khalaf","year":"2019","journal-title":"Lancet Oncol"},{"key":"2026070905480852100_bib28","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1093\/jnci\/djab062","article-title":"Association of health-care system with prostate cancer-specific mortality in African American and non-hispanic white men","volume":"113","author":"Klebaner","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"2026070905480852100_bib29","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.3390\/cancers13122939","article-title":"Evaluation of darolutamide (ODM201) efficiency on androgen receptor mutants reported to date in prostate cancer patients","volume":"13","author":"Lallous","year":"2021","journal-title":"Cancers"},{"key":"2026070905480852100_bib30","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/annonc\/mdt136","article-title":"Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)","volume":"24","author":"Loriot","year":"2013","journal-title":"Ann Oncol"},{"key":"2026070905480852100_bib31","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1158\/0008-5472.CAN-12-4414","article-title":"A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer","volume":"73","author":"Mitsiades","year":"2013","journal-title":"Cancer Res"},{"key":"2026070905480852100_bib32","doi-asserted-by":"crossref","first-page":"T19","DOI":"10.1530\/ERC-21-0098","article-title":"Androgen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancer","volume":"28","author":"Mitsiades","year":"2021","journal-title":"Endocr Relat Cancer"},{"key":"2026070905480852100_bib33","doi-asserted-by":"crossref","first-page":"12007","DOI":"10.1038\/srep12007","article-title":"Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies","volume":"5","author":"Moilanen","year":"2015","journal-title":"Sci Rep"},{"key":"2026070905480852100_bib34","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1093\/annonc\/mdt138","article-title":"Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide","volume":"24","author":"Noonan","year":"2013","journal-title":"Ann Oncol"},{"key":"2026070905480852100_bib35","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1158\/1535-7163.MCT-15-0892","article-title":"The effect of F877L and T878A mutations on androgen receptor response to enzalutamide","volume":"15","author":"Prekovic","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"2026070905480852100_bib36","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"2026070905480852100_bib37","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac9511","article-title":"Plasma AR and abiraterone-resistant prostate cancer","volume":"7","author":"Romanel","year":"2015","journal-title":"Sci Transl Med"},{"key":"2026070905480852100_bib38","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026070905480852100_bib39","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.2217\/fon-2022-0943","article-title":"Efficacy and safety of darolutamide in Black\/African-American patients from the phase III ARAMIS study","volume":"18","author":"Shore","year":"2022","journal-title":"Future Oncol"},{"key":"2026070905480852100_bib40","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"2026070905480852100_bib41","doi-asserted-by":"crossref","first-page":"5847","DOI":"10.3390\/ijms21165847","article-title":"Deep learning modeling of androgen receptor responses to prostate cancer therapies","volume":"21","author":"Snow","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2026070905480852100_bib42","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1056\/NEJMoa2003892","article-title":"Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer","volume":"382","author":"Sternberg","year":"2020","journal-title":"N Engl J Med"},{"key":"2026070905480852100_bib43","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1002\/ijc.32242","article-title":"Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models","volume":"145","author":"Sugawara","year":"2019","journal-title":"Int J Cancer"},{"key":"2026070905480852100_bib44","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.trecan.2020.04.010","article-title":"Advanced prostate cancer: treatment advances and future directions","volume":"6","author":"Swami","year":"2020","journal-title":"Trends Cancer"},{"key":"2026070905480852100_bib45","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"2026070905480852100_bib46","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1158\/0008-5472.CAN-13-2876","article-title":"Androgen receptor splice variants determine taxane sensitivity in prostate cancer","volume":"74","author":"Thadani-Mulero","year":"2014","journal-title":"Cancer Res"},{"key":"2026070905480852100_bib47","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","article-title":"Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer","volume":"381","author":"de Wit","year":"2019","journal-title":"N Engl J Med"},{"key":"2026070905480852100_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100276","article-title":"Androgen receptor splicing variant 7 (ARV7) inhibits docetaxel sensitivity by inactivating the spindle assembly checkpoint","volume":"296","author":"Yu","year":"2021","journal-title":"J Biol Chem"},{"key":"2026070905480852100_bib49","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1158\/1535-7163.MCT-20-0015","article-title":"Cross-resistance among next-generation antiandrogen drugs through the AKR1C3\/AR-V7 Axis in advanced prostate cancer","volume":"19","author":"Zhao","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"2026070905480852100_bib50","doi-asserted-by":"crossref","first-page":"7992","DOI":"10.1158\/0008-5472.CAN-10-0585","article-title":"Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer","volume":"70","author":"Zhu","year":"2010","journal-title":"Cancer Res"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/32\/6\/ERC-24-0188.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/32\/6\/ERC-24-0188.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-24-0188\/247010\/erc-24-0188.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-24-0188\/247010\/erc-24-0188.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T09:48:19Z","timestamp":1783590499000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/32\/6\/e240188\/26096\/Real-world-effectiveness-of-darolutamide-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1530\/erc-24-0188","relation":{},"ISSN":["1479-6821","1351-0088"],"issn-type":[{"value":"1479-6821","type":"electronic"},{"value":"1351-0088","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,1]]},"article-number":"e240188"}}